A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating The Efficacy And Safety Of Pertuzumab In Combination With Trastuzumab And Chemotherapy In Patients With Her2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JACOB
- Sponsors Roche
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 18 May 2016 The trial was completed in Finland.